MX2017005925A - Metodos de producción de proteínas de cadena doble en bacterias. - Google Patents

Metodos de producción de proteínas de cadena doble en bacterias.

Info

Publication number
MX2017005925A
MX2017005925A MX2017005925A MX2017005925A MX2017005925A MX 2017005925 A MX2017005925 A MX 2017005925A MX 2017005925 A MX2017005925 A MX 2017005925A MX 2017005925 A MX2017005925 A MX 2017005925A MX 2017005925 A MX2017005925 A MX 2017005925A
Authority
MX
Mexico
Prior art keywords
methods
producing
bacteria
chain proteins
chain
Prior art date
Application number
MX2017005925A
Other languages
English (en)
Inventor
Reilly Dorothea
GIULIANOTTI James
Aurori Kieran
C Simmons Laura
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2017005925A publication Critical patent/MX2017005925A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Se proporcionan en la presente métodos de producción de un polipéptido recombinante que contiene dos cadenas, taL como una proteína de receptor de células T monoclonales inmuno movilizador contra el cáncer (ImmTAC) que incluye una cadena alfa y una cadena beta. En particular, se proporcionan métodos para la producción de proteínas secretoras heterólogas en bacterias, mediante el uso de vectores de expresión y procesos de cultivo optimizados.
MX2017005925A 2014-11-05 2015-11-05 Metodos de producción de proteínas de cadena doble en bacterias. MX2017005925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075798P 2014-11-05 2014-11-05
PCT/US2015/059342 WO2016073794A1 (en) 2014-11-05 2015-11-05 Methods of producing two chain proteins in bacteria

Publications (1)

Publication Number Publication Date
MX2017005925A true MX2017005925A (es) 2017-11-08

Family

ID=54602036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005925A MX2017005925A (es) 2014-11-05 2015-11-05 Metodos de producción de proteínas de cadena doble en bacterias.

Country Status (15)

Country Link
US (3) US10066002B2 (es)
EP (2) EP3215525B1 (es)
JP (2) JP6770966B2 (es)
KR (1) KR102544705B1 (es)
CN (2) CN107075548B (es)
AU (2) AU2015342964B2 (es)
BR (1) BR112017009262A2 (es)
CA (1) CA2966573A1 (es)
ES (1) ES2819256T3 (es)
HR (1) HRP20201351T1 (es)
IL (2) IL252028B (es)
MX (1) MX2017005925A (es)
RU (2) RU2739500C2 (es)
SI (1) SI3215525T1 (es)
WO (1) WO2016073794A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2966558C (en) * 2014-11-05 2024-03-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
US10066002B2 (en) 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
ES2930681T3 (es) * 2016-03-16 2022-12-20 Immatics Biotechnologies Gmbh Linfocitos T transfectados y receptores de linfocito T para el uso en la inmunoterapia contra el cáncer
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
DE102017114737A1 (de) * 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
WO2019038338A1 (en) 2017-08-23 2019-02-28 Sandoz Ag PROTEIN EXPRESSION SYSTEM WITH MULTIPLE GENIC COPIES
TW202031899A (zh) * 2018-11-05 2020-09-01 美商建南德克公司 在原核宿主細胞中產生二鏈蛋白質之方法
CN109371049A (zh) * 2018-11-14 2019-02-22 天津大学 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (es)
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2364568A1 (en) * 1999-03-17 2000-09-21 Adrian Woolfson Method for refolding molecules of polypeptides containing ig domains
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU3944002A (en) * 2000-11-03 2002-05-27 Genentech Inc Metabolic rate shifts in fermentations expressing recombinant proteins
DK1356052T3 (da) 2000-12-14 2008-12-08 Genentech Inc Produktion af hele antistoffer i prokaryotiske celler
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
ATE382053T1 (de) * 2001-08-27 2008-01-15 Genentech Inc System zur antikörperexpression und- synthese
MXPA04001974A (es) * 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
KR20110027851A (ko) 2002-07-19 2011-03-16 애보트 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
EP2186527A1 (en) 2003-11-28 2010-05-19 Micromet AG Compositions comprising polypeptides
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
PT2805728T (pt) 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
JP4501451B2 (ja) 2004-02-18 2010-07-14 株式会社豊田自動織機 塗料組成物、塗料組成物を用いた透明性保護膜の製造方法および透明性保護膜を有する有機ガラス
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
BR122019012028B1 (pt) 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
CA2577082A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
KR101453570B1 (ko) * 2005-12-02 2014-10-22 제넨테크, 인크. Ｉｌ-22 및 ｉｌ-22ｒ에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
PL2520590T3 (pl) 2007-04-03 2019-02-28 Amgen Research (Munich) Gmbh Domena wiążąca wykazująca krzyżową swoistość gatunkową
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
CN105001330B (zh) 2010-04-23 2020-05-01 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
WO2012106615A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
ES2682081T3 (es) 2011-10-11 2018-09-18 F. Hoffmann-La Roche Ag Ensamblaje mejorado de anticuerpos biespecíficos
WO2014134577A1 (en) 2013-03-01 2014-09-04 Sio2 Medical Products, Inc. Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus
EP2981286A4 (en) 2013-04-05 2016-08-24 Hoffmann La Roche ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
SG10202108497TA (en) * 2013-04-19 2021-09-29 Sutro Biopharma Inc Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
US10066002B2 (en) 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
CA2966558C (en) 2014-11-05 2024-03-12 Genentech, Inc. Methods of producing two chain proteins in bacteria

Also Published As

Publication number Publication date
CN113699203A (zh) 2021-11-26
AU2021236533A1 (en) 2021-10-21
EP3753948A1 (en) 2020-12-23
US20190085045A1 (en) 2019-03-21
BR112017009262A2 (pt) 2018-03-06
AU2015342964B2 (en) 2021-06-24
JP2021019601A (ja) 2021-02-18
IL252028A0 (en) 2017-06-29
WO2016073794A8 (en) 2017-05-18
KR20170075014A (ko) 2017-06-30
AU2015342964A1 (en) 2017-06-15
CA2966573A1 (en) 2016-05-12
HRP20201351T1 (hr) 2020-11-27
EP3215525B1 (en) 2020-07-29
CN107075548B (zh) 2021-08-10
ES2819256T3 (es) 2021-04-15
RU2020141422A (ru) 2021-01-13
RU2739500C2 (ru) 2020-12-25
IL287373A (en) 2021-12-01
KR102544705B1 (ko) 2023-06-15
SI3215525T1 (sl) 2020-11-30
IL252028B (en) 2021-12-01
JP6770966B2 (ja) 2020-10-21
RU2017119396A3 (es) 2019-06-04
US20220162286A1 (en) 2022-05-26
US10066002B2 (en) 2018-09-04
CN107075548A (zh) 2017-08-18
US20160159880A1 (en) 2016-06-09
EP3215525A1 (en) 2017-09-13
US11091530B2 (en) 2021-08-17
AU2021236533B2 (en) 2024-02-01
JP6997273B2 (ja) 2022-02-21
RU2017119396A (ru) 2018-12-05
WO2016073794A1 (en) 2016-05-12
JP2017533730A (ja) 2017-11-16

Similar Documents

Publication Publication Date Title
MX2017005925A (es) Metodos de producción de proteínas de cadena doble en bacterias.
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
MX2023001403A (es) Neoantigenos y metodos de su uso.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MX2022013540A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
MX2019003886A (es) Receptores de antigenos quimericos para el tratamiento del cancer.
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2021011696A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
MX2021008142A (es) Metodos para cosechar cultivos de celulas de mamifero.
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
AR102879A1 (es) Métodos para el tratamiento de tumores cerebrales
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
PH12019502298A1 (en) Monoclonal antibody to pd-l1
PH12017500047A1 (en) Dual cistronic bacterial expression system
MX2021001129A (es) Metodo de purificacion de antigenos.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2017005930A (es) Metodo de produccion de proteinas de cadena doble en bacterias.
MX2018003445A (es) Expresion de proteinas que contienen fc.